Document is current
Any future updates will be listed below
-
Authors
Baird, David P. https://orcid.org/0000-0002-6338-3788
Zang, Jinnan
Connor, Katie L.
Teenan, Oliver
Reck, Maximilian https://orcid.org/0000-0001-8829-5031
Cairns, Carolynn
Sutherland, Callum
Bell, Rachel M. B.
Traynor, Jamie P. https://orcid.org/0000-0002-4339-0366
Wong, Ryan
Ferenbach, David A. https://orcid.org/0000-0002-9202-1428
Hughes, Jeremy
Mark, Patrick B. https://orcid.org/0000-0003-3387-2123
Maxwell, Alexander P. https://orcid.org/0000-0002-6110-7253
McKay, Gareth J.
Simpson, David A. https://orcid.org/0000-0003-0157-1211
Conway, Bryan R. https://orcid.org/0000-0002-2888-9249
Denby, Laura https://orcid.org/0000-0003-1277-708X
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 9 September 2025
First Online: 15 October 2025
Competing interests
: These authors declare no competing interests: J.Z., K.L.C., O.T., R.K.Y.W., M.R., C.C., J.P.T., J.H., A.P.M., G.J.M., D.A.S. and L.D. These authors declare the following competing interests: P.B.M. reports lecture or advisory board honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Pharmacosmos, Astellas, Vifor, GSK and research funding from AstraZeneca and Boehringer Ingelheim outside the submitted work. B.R.C. reports consultancy from Argenx and research funding from AstraZeneca outside the submitted work. D.P.B. is listed as a co-inventor on a patent application covering urinary protein biomarkers in chronic kidney disease outside the submitted work.
